STOK(STOK)
STOK
ANALYST COVERAGE15 analysts
BUY
▲ +37.8%upside to target
L $35.00
Med $40.00consensus
H $60.00PRICE
Prev Close
30.08
Open
30.00
Day Range28.61 – 30.55
28.61
30.55
52W Range9.09 – 40.22
9.09
40.22
64% of range
VOLUME & SIZE
Avg Volume
729.5K
FUNDAMENTALS
P/E Ratio
-10.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.55
High vol
TECHNICAL
RSI (14)
37
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 104 days
Aug 31
Key MetricsTTM
Market Cap$1.81B
Revenue TTM$32.08M
Net Income TTM-$169.77M
Free Cash Flow-$147.69M
Gross Margin90.4%
Operating Margin-577.5%
Net Margin-529.2%
Return on Equity-48.8%
Return on Assets-38.3%
Debt / Equity0.01
Current Ratio8.99
EPS TTM$-2.69
STOK News
About
stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Edward Kaye
Website
Doug SnowDirector of Communications & Investor Relations
Adrian R. KrainerCo-Founder & Independent Director
Barry S. Ticho FACCChief Medical Officer
Edward KayeAdvisor & Director
Ian F. SmithChief Executive Officer & Director
Jason HoittChief Patient Officer
Jonathan AllanCorporate Secretary & General Counsel
Thomas Edward LeggettChief Financial Officer
Dawn KalmarChief of Corporate Affairs & Strategic Partnerships
Isabel AznarezCo-Founder, Head of Research & Senior Vice President
Sara Den BestenChief People Officer
Susan WillsonVice President of Corporate Communications